News and Trends 1 Nov 2022 First to market doesn’t guarantee success A comparison of two cancer drugs, Opdivo and Keytruda, reveals that being the first-to-market is not necessarily the main factor in a drug’s success. For the first four years since their approval, the anticancer drug Opdivo outperformed Keytruda in sales. But this trend reversed in 2018, with Keytruda’s sales becoming higher than Opdivo’s. Recently, a […] November 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 TrialSpark partners with Sanofi to acquire and develop clinical-stage novel therapies TrialSpark has announced a new partnership with global pharma company Sanofi to explore novel methods of bringing new treatments to patients faster and more efficiently. The collaboration will focus on jointly pursuing the acquisition/in-licensing and development of best-in-class, clinical-stage phase II and phase III drug candidates in areas of high unmet patient need. The partnership […] October 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2022 Optics11 Life receives €5 million in funding for drug development and rollout of products Expanded offerings for drug development and regenerative medicines will be the focus of €5 million ($4.8 million) funding raised by Optics11 Life. The funding from Forward.ONE and returning investor, Value Creation Capital, was announced today (September 28) and will support the rollout of new products applying the company’s technology for experiments at scale requiring high-throughput […] September 28, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2022 SiSaf reveals positive preclinical data in siRNA program to treat osteopetrosis SiSaf Ltd, an RNA delivery and therapeutics company, has announced positive data confirming safety and efficacy of its Bio-Courier next generation silicon stabilized hybrid lipid nanoparticles (sshLNP) as an effective non-viral delivery system for autosomal dominant osteopetrosis type 2 (ADO2) siRNA therapy. The data was presented at the American Society of Bone and Mineral Research […] September 12, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2022 Salipro Biotech obtains patents for direct extraction of membrane proteins and library generation Salipro Biotech AB, a Swedish biotech company with a platform for the stabilization of membrane proteins for drug development, has had patents issued by both the U.S. Patent and Trademark Office and the China National Intellectual Property Administration. The patent is entitled “Saposin lipoprotein particles and libraries from crude membranes.” The patents cover the company’s […] September 6, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2022 Evotec SE acquires highly-flexible drug manufacturing space for €1 A clinical and commercial manufacturing platform for small molecule therapeutics has expanded following an acquisition signed for. Evotec SE made the announcement today (August 25) after signing the contract yesterday for €1 to take Central Glass Germany GmbH from Japanese manufacturing company Central Glass Co. Ltd. It will now operate as Evotec Drug Substance (Germany) […] August 25, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jul 2022 GenScript ProBio enters strategic partnerships with two South Korean biotechs GenScript ProBio, the CDMO segment of the leading biotech GenScript, has entered into a strategic partnership memorandum of understanding (MOU) with DAAN Bio Therapeutics for the discovery and development of novel drugs and with ACT Therapeutics to develop new CAR-T cell therapies. With offices located in the U.S., the Netherlands, China, Singapore and Japan, GenScript […] July 14, 2022 - 3 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
Sponsored by Hub Organoids 12 Jul 2022 The organoid era: bringing patient-relevant preclinical models to the lab Drug development is a lengthy and costly process that takes at least 10 years on average from drug discovery to commercialization, requiring billions of dollars in investment. However, over 90% of new drugs that are tested in clinical trials fail. Organoids — three-dimensional, patient-derived mini-organs in a dish — offer a solution to this challenge. […] July 12, 2022 - 7 minutesmins - By Sudha Sundaram Share WhatsApp Twitter Linkedin Email
Sponsored by Merck 26 Jan 2022 Top Reasons to Outsource Your Early Clinical Pipeline to a CDMO Biotech firms partner with contract development and manufacturing organizations (CDMOs) to leverage their expertise in process development, optimization, and scale-up. In this article, we share an exclusive sneak-peek into a recent survey, which explores the main reasons why biotech companies collaborate with CDMOs at different stages of drug development. To make a new drug candidate […] January 26, 2022 - 8 minutesmins - By Sudha Sundaram Share WhatsApp Twitter Linkedin Email
Opinion 31 Aug 2021 Cloud Foundations for R&D: Designing the Future of Life Sciences In recent years, artificial intelligence has been hailed as the next big thing in drug discovery. But to leverage the full potential of this technology the life sciences industry first needs to pay attention to experimental design and data collection. We embrace the latest digital technologies to enhance almost everything in our daily lives—from how […] August 31, 2021 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 7 Jun 2021 The Post-Covid Future of AI for Drug Development With the global Covid-19 outbreak in early 2020, pharma companies and biotechs have increasingly turned to artificial intelligence to improve precision and speed in drug development. Artificial intelligence (AI), the ability of machines to learn from new input, is a broad term for a range of computing methods. Recommendation engines used by online shopping or […] June 7, 2021 - 11 minutesmins - By Matthew Williams Share WhatsApp Twitter Linkedin Email
Opinion 19 Apr 2021 The Hidden Costs of Mismanaged R&D Projects in Biotech and Pharma Mismanagement of R&D projects in biotech and pharma is more common than one might think and can result in high development costs and eventual clinical failure. Can we do something about it? Biotechnology and pharmaceutical businesses are synonymous with both a high risk and an even bigger investment. Bringing new drugs to the market can […] April 19, 2021 - 7 minutesmins - By Auste Kanapeckaite Share WhatsApp Twitter Linkedin Email